⇢ Basic Information
Cagliar was approved by the US Food and Drug Administration (FDA) on March 29, 2013 and was approved by the European Medicines Agency (EMA) on November 15, 2013, on July 4, 2014. It was approved by the Japan Pharmaceutical Medical Device Integration Agency (PMDA) and was approved by the China Food and Drug Administration (CFDA) on September 29, 2017. The drug was originally researched by Tanabe Mitsubishi Pharmaceuticals. Johnson & Johnson's Yangsen Pharmaceutical was authorized by the US and the European Union in 2012. The drug is marketed in the US market under the trade name Invokana®. The Japanese region is produced and sold by Tanabe Mitsubishi, and is promoted jointly by the First Sankyo Co., Ltd. On March 7, 2018, Tai Tien Pharma, a subsidiary of Japan's Tanabe Mitsubishi, was sold under the trade name Canaglu® in Taiwan. The market was also launched by Tanabe Mitsubishi after the launch of Canaglu®. The second market.
Cagliflozin is a sodium-glucose transporter 2 (SGLT2) inhibitor. 90% of renal glucose reabsorption is achieved by SGLT2 protein (SGL1 is responsible for the remaining 10%). Cagliflozin reduces the re-absorption of filtered glucose and lowers the renal sugar threshold, thereby increasing urine glucose excretion. This medicine aids diet control and exercise to improve glycemic control in adults with type 2 diabetes.
Invokana® is an oral film tablet with a net content of 100 mg or 300 mg per tablet. The recommended starting dose is 100 mg each time and is taken once a day before the first meal.
⇢ Structural formula
Mechanism
⇲
⇲
⇲
Canagliplozin is the first FDA-approved SGLT2 inhibitor for the treatment of type 2 diabetes in adult patients. SGLT is a glucose transporter with two subtypes, SGLT1 and SGLT2, which are distributed in the intestinal mucosa and renal tubules, respectively, and are capable of transporting glucose into the bloodstream. Cagliflozin inhibits SLCT2, so that glucose in the renal tubules cannot be smoothly reabsorbed into the blood and excreted in the urine, thereby lowering blood glucose concentration.
Synthetic route
↧
↧
↣ ↣
↧
↡
⇢ Research key data
This article is reproduced from：https://news.pharmacodia.com/news/html/info/info-detail.html?id=29470
